Augusto Silvio Nunes, Martens Pieter
Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Kauffman Center for Heart Failure Treatment and Recovery, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Curr Heart Fail Rep. 2023 Oct;20(5):374-381. doi: 10.1007/s11897-023-00623-z. Epub 2023 Aug 26.
The goal of the current review is to give an overview regarding the pathophysiology of iron deficiency in heart failure and how different laboratory tests change in the setting of heart failure.
Recent studies have questioned the current employed definition of iron deficiency in the field of heart failure, as patients with ferritin < 100ng/ml but TSAT > 20% have a better prognosis, no iron deficiency on bone marrow staining, and altered treatment response to ferric carboxymaltose. This review summarizes changes in iron parameters in the setting of heart failure and underscores the importance of a reduced bioavailability of iron documented by a low serum iron or TSAT, irrespective of the presence of anemia.
本次综述的目的是概述心力衰竭中铁缺乏的病理生理学，以及在心力衰竭情况下不同实验室检查的变化。
近期研究对心力衰竭领域目前采用的铁缺乏定义提出了质疑，因为铁蛋白<100ng/ml但转铁蛋白饱和度>20%的患者预后较好，骨髓染色无铁缺乏，且对羧基麦芽糖铁的治疗反应有所改变。本综述总结了心力衰竭情况下铁参数的变化，并强调了低血清铁或转铁蛋白饱和度所证明的铁生物利用度降低的重要性，无论是否存在贫血。
